Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Neoplasms of the CNS

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 107 articles: HTML format

Single Articles

August 2025
1. FENG Y, Haupt B, Huynh TT, Meshaw R, et al
   Longitudinal Imaging Reveals Tumor Uptake and Prolonged Retention of Bispecific T Cell-Engaging Antibody in GBM via Passive and Active Mechanisms.
   Clin Cancer Res. 2025;31:3537-3549.
   PubMed     Abstract available
   
   
   
2. HABASHY KJ, Synold TW, Feng Y, Gomez C, et al
   Pharmacokinetic Analysis of Carboplatin and Fluorescein Brain Retention following Ultrasound-Based Blood-Brain Barrier Opening.
   Clin Cancer Res. 2025;31:3562-3570.
   PubMed     Abstract available
   
   
   
3. VOLOVETZ J, Buchwald LV, Straede K, Kjaer A, et al
   The importance of integrating surgical resection into preclinical glioblastoma modeling.
   Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0788.
   PubMed     Abstract available
   
   
   
4. FAROUK SAIT S, O'Donohue TJ, Bale T, Bowman A, et al
   Improving Global Access to Genomic Profiling in Rare Pediatric Cancers.
   Clin Cancer Res. 2025;31:3285-3295.
   PubMed     Abstract available
   
   
   July 2025
5. ZHANG N, Wu X, Yang L, Xiao F, et al
   Editor's Note: FoxM1 Inhibition Sensitizes Resistant Glioblastoma Cells to Temozolomide by Downregulating the Expression of DNA-Repair Gene Rad51.
   Clin Cancer Res. 2025;31:3098.
   PubMed    
   
   
   
6. ZHOU F, Sun Y, Chen X, Wu D, et al
   UBE2T-mediated HP1alpha ubiquitination enhances nucleolar function and promotes the progression of IDH1/TP53-mutant glioma.
   Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-25-0261.
   PubMed     Abstract available
   
   
   
7. VAUBEL RA, Zhang W, Oh JH, Mladek AC, et al
   Pre-clinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-wildtype Glioblastoma.
   Clin Cancer Res. 2025 Jul 1. doi: 10.1158/1078-0432.CCR-25-0244.
   PubMed     Abstract available
   
   
   
8. VAN SCHAIK TA, Chen KS, Kanaya N, Moreno-Lama L, et al
   Antitumor Immunity Mediated by Engineered Stem Cells Exploiting TRAIL-Induced Cell Death and FLT3L Immunomodulation.
   Clin Cancer Res. 2025;31:2793-2813.
   PubMed     Abstract available
   
   
   June 2025
9. YU B, Kline C, Hoare O, Jung J, et al
   Measles oncolytic virus as an immunotherapy for recurrent/refractory pediatric medulloblastoma and atypical teratoid rhabdoid tumor: results from PNOC005.
   Clin Cancer Res. 2025 Jun 20. doi: 10.1158/1078-0432.CCR-24-3721.
   PubMed     Abstract available
   
   
   
10. NIA HT, Datta M, Kumar AS, Siri S, et al
    Solid stress estimations via intraoperative 3D navigation in patients with brain tumors.
    Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-4159.
    PubMed     Abstract available
    
    
    
11. KIM AR, Jeon SH, Park J, Kim ES, et al
    Co-blockade of TGFbeta and PD-1 reinvigorates glioblastoma-infiltrating CD8+ T cells that characteristically upregulate TGFbetaR expression.
    Clin Cancer Res. 2025 Jun 3. doi: 10.1158/1078-0432.CCR-24-2184.
    PubMed     Abstract available
    
    
    
12. BHANJA D, Zhu J, Wilding H, Benavides-Vasquez J, et al
    A population-level real-world analysis and single-center validation of melanoma brain metastasis epidemiology following dual-agent immunotherapy.
    Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-24-2681.
    PubMed     Abstract available
    
    
    
13. RITZMANN TA, Hodgkinson R, Shanmugavadivel S
    Neither small adults nor big children: Doing better for TYAs with brain tumors.
    Clin Cancer Res. 2025 Jun 2. doi: 10.1158/1078-0432.CCR-25-1007.
    PubMed     Abstract available
    
    
    May 2025
14. BEICHERT J, Hoffmann DC, Winkler F, Ratliff M, et al
    Innovative Therapeutic Strategies Targeting the Network Architecture of Glioblastoma.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-25-0018.
    PubMed     Abstract available
    
    
    
15. GREEN AL, Minard CG, Liu X, Safgren SL, et al
    Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial.
    Clin Cancer Res. 2025;31:1587-1595.
    PubMed     Abstract available
    
    
    April 2025
16. FIORICA PN, Golmard L, Kim J, Bao R, et al
    Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition.
    Clin Cancer Res. 2025;31:1491-1503.
    PubMed     Abstract available
    
    
    
17. PERRINO MR, Jongmans MCJ, Tomlinson GE, Greer MC, et al
    Update on Cancer and Central Nervous System Tumor Surveillance in Pediatric NF2-, SMARCB1-, and LZTR1-Related Schwannomatosis.
    Clin Cancer Res. 2025;31:1400-1406.
    PubMed     Abstract available
    
    
    March 2025
18. ZHOU W, Yue Q, Yuan Y, Huang Q, et al
    Visualization of P2X7 Receptors in Living Human Gliomas: an 18F-GSK1482160 PET Imaging and Neuropatholopy Study.
    Clin Cancer Res. 2025 Mar 17. doi: 10.1158/1078-0432.CCR-24-2830.
    PubMed     Abstract available
    
    
    
19. PEREIRA R, Mackay A, Grabovska Y, Bradley A, et al
    The spectrum of IDH- and H3-wildtype high-grade glioma subgroups occurring across teenage and young adult patient populations.
    Clin Cancer Res. 2025 Mar 10. doi: 10.1158/1078-0432.CCR-24-1256.
    PubMed     Abstract available
    
    
    February 2025
20. ALI MF, Riviere-Cazaux C, Johnson SH, Salvatori R, et al
    Personalized tumor-specific amplified DNA junctions in peripheral blood of patients with glioblastoma.
    Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-3233.
    PubMed     Abstract available
    
    
    
21. LAMOUREUX AA, Fisher MJ, Lemelle L, Pfaff E, et al
    Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions.
    Clin Cancer Res. 2025;31:561-572.
    PubMed     Abstract available
    
    
    January 2025
22. TILL JE, Seewald NJ, Yazdani Z, Wang Z, et al
    Corticosteroid-dependent association between prognostic peripheral blood cell-free DNA levels and neutrophil-mediated NETosis in patients with glioblastoma.
    Clin Cancer Res. 2025 Jan 31. doi: 10.1158/1078-0432.CCR-24-3169.
    PubMed     Abstract available
    
    
    
23. STEFAN D, Lesueur P, Lequesne J, Feuvret L, et al
    Olaparib, temozolomide and concomitant radiotherapy for partially or biopsy-only glioblastoma first-line treatment: results from the OLA-TMZ-RTE-01 phase 1 study.
    Clin Cancer Res. 2025 Jan 30. doi: 10.1158/1078-0432.CCR-24-2974.
    PubMed     Abstract available
    
    
    
24. LEE EQ, Alexander BM, Romo CG, Supko JG, et al
    Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
    Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-2311.
    PubMed     Abstract available
    
    
    
25. SINGH S, Bradford D, Chatterjee S, Li X, et al
    FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
    Clin Cancer Res. 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439.
    PubMed     Abstract available
    
    
    
26. MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al
    Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
    Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977.
    PubMed     Abstract available
    
    
    December 2024
27. FISCHER GM, Lamba N, Vogelzang J, Aizer A, et al
    Genomic profiling reveals SMARCA4 mutations are associated with shorter overall and intracranial progression free survival in melanoma brain metastasis patients.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-0301.
    PubMed     Abstract available
    
    
    
28. RIVIERE-CAZAUX C, Dong X, Mo W, Kumar R, et al
    Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA.
    Clin Cancer Res. 2024 Dec 23. doi: 10.1158/1078-0432.CCR-24-1814.
    PubMed     Abstract available
    
    
    
29. OLOW A, Mueller S, Yang X, Hashizume R, et al
    Editor's Note: BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
    Clin Cancer Res. 2024;30:5494.
    PubMed    
    
    
    November 2024
30. IWAMOTO FM, Tanguturi SK, Nayak L, Wang TJ, et al
    Re-irradiation plus pembrolizumab: Phase II study for recurrent glioblastoma patients.
    Clin Cancer Res. 2024 Nov 8. doi: 10.1158/1078-0432.CCR-24-1629.
    PubMed     Abstract available
    
    
    
31. TOBOCHNIK S, Regan MS, Dorotan MKC, Reich D, et al
    Pilot Trial of Perampanel on Peritumoral Hyperexcitability in Newly Diagnosed High-grade Glioma.
    Clin Cancer Res. 2024 Nov 5:OF1-OF9. doi: 10.1158/1078-0432.CCR-24-1849.
    PubMed     Abstract available
    
    
    October 2024
32. CHAMSEDDINE I, Shah K, Lee H, Ehret F, et al
    Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis.
    Clin Cancer Res. 2024;30:4424-4433.
    PubMed     Abstract available
    
    
    September 2024
33. GROMMES C, Nandakumar S, Schaff LR, Gavrilovic I, et al
    A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma.
    Clin Cancer Res. 2024;30:4005-4015.
    PubMed     Abstract available
    
    
    
34. RIXE O, Villano JL, Wesolowski R, Noonan AM, et al
    A first-in-human phase 1 study of BXQ-350, a first-in-class sphingolipid metabolism regulator, in patients with advanced/recurrent solid tumors or high-grade gliomas.
    Clin Cancer Res. 2024 Sep 12. doi: 10.1158/1078-0432.CCR-24-1721.
    PubMed     Abstract available
    
    
    
35. VAN DER VAART T, Wijnenga MMJ, van Garderen K, Dubbink HJ, et al
    Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study.
    Clin Cancer Res. 2024;30:3837-3844.
    PubMed     Abstract available
    
    
    
36. GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al
    A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161.
    PubMed     Abstract available
    
    
    August 2024
37. SUROV A, Borggrefe J
    Translational Imaging in Cerebral Tumors.
    Clin Cancer Res. 2024 Aug 23. doi: 10.1158/1078-0432.CCR-24-2013.
    PubMed     Abstract available
    
    
    
38. KARSCHNIA P, Tonn JC, Cahill DP
    The infiltrative margins in glioblastoma: important is what has been left behind.
    Clin Cancer Res. 2024 Aug 20. doi: 10.1158/1078-0432.CCR-24-1819.
    PubMed     Abstract available
    
    
    
39. BARTOS LM, Quach S, Zenatti V, Kirchleitner SV, et al
    Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome.
    Clin Cancer Res. 2024 Aug 16. doi: 10.1158/1078-0432.CCR-24-1563.
    PubMed     Abstract available
    
    
    
40. PASCUAL-PASTO G, McIntyre B, Giudice AM, Alikarami F, et al
    Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas with Local and Systemic Delivery of CAR T Cells.
    Clin Cancer Res. 2024;30:3578-3591.
    PubMed     Abstract available
    
    
    
41. LEE MD, Jain R, Galbraith K, Chen A, et al
    T2-FLAIR Mismatch Sign Predicts DNA Methylation Subclass and CDKN2A/B Status in IDH-Mutant Astrocytomas.
    Clin Cancer Res. 2024;30:3512-3519.
    PubMed     Abstract available
    
    
    July 2024
42. GREWAL EP, Richardson LGK, Sun J, Ramapriyan R, et al
    Mutant IDH modulates suppressive myeloid populations in malignant glioma.
    Clin Cancer Res. 2024 Jul 23. doi: 10.1158/1078-0432.CCR-24-1056.
    PubMed     Abstract available
    
    
    
43. REINECKE D, Ruess D, Meissner AK, Furtjes G, et al
    Streamlined intraoperative brain tumor classification and molecular subtyping in stereotactic biopsies using stimulated Raman histology and deep learning.
    Clin Cancer Res. 2024 Jul 8. doi: 10.1158/1078-0432.CCR-23-3842.
    PubMed     Abstract available
    
    
    
44. GRAILLON T, Romanet P, Camilla C, Gelin C, et al
    A Cohort Study of CNS Tumors in Multiple Endocrine Neoplasia Type 1.
    Clin Cancer Res. 2024;30:2835-2845.
    PubMed     Abstract available
    
    
    June 2024
45. GAO M, Liu Z, Zang H, Wu X, et al
    A Histopathologic Correlation Study Evaluating Glymphatic Function in Brain Tumors by Multi-Parametric MRI.
    Clin Cancer Res. 2024 Jun 7. doi: 10.1158/1078-0432.CCR-24-0150.
    PubMed     Abstract available
    
    
    
46. AHLUWALIA MS, Ozair A, Drappatz J, Ye X, et al
    Evaluating the Base Excision Repair Inhibitor TRC102 and Temozolomide for patients with Recurrent Glioblastoma in the Phase 2 Adult Brain Tumor Consortium Trial BERT.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-23-4098.
    PubMed     Abstract available
    
    
    
47. PARK YW, Choi KS, Foltyn-Dumitru M, Brugnara G, et al
    Incorporating Supramaximal Resection into Survival Stratification of IDH-Wildtype Glioblastoma: A Refined Multi-institutional Recursive Partitioning Analysis.
    Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-23-3845.
    PubMed     Abstract available
    
    
    May 2024
48. JAIN S, Griffith JI, Porath KA, Rathi S, et al
    Bystander effects, pharmacokinetics, and linker-payload stability of EGFR-targeting antibody-drug conjugates Losatuxizumab vedotin and Depatux-M in glioblastoma models.
    Clin Cancer Res. 2024 May 14. doi: 10.1158/1078-0432.CCR-24-0426.
    PubMed     Abstract available
    
    
    
49. NASSER AM, Melamed L, Wetzel E, Chang CC, et al
    CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition.
    Clin Cancer Res. 2024 May 8. doi: 10.1158/1078-0432.CCR-24-0562.
    PubMed     Abstract available
    
    
    
50. CHOI SH, Stuckey DW, Pignatta S, Reinshagen C, et al
    Editor's Note: Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNbeta in Glioblastomas.
    Clin Cancer Res. 2024;30:1993.
    PubMed    
    
    
    April 2024
51. ABDULLAH KG
    Classifying glioma via liquid biopsy--progress towards an unmet clinical need.
    Clin Cancer Res. 2024 Apr 23. doi: 10.1158/1078-0432.CCR-24-0423.
    PubMed     Abstract available
    
    
    
52. JOHANNS TM, Garfinkle EAR, Miller KE, Livingstone AJ, et al
    Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma.
    Clin Cancer Res. 2024 Apr 19. doi: 10.1158/1078-0432.CCR-23-3077.
    PubMed     Abstract available
    
    
    
53. GRIESINGER AM, Calzadilla AJ, Grimaldo E, Donson AM, et al
    Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma.
    Clin Cancer Res. 2024;30:1544-1554.
    PubMed     Abstract available
    
    
    
54. WILBUR HC, Le DT, Agarwal P
    Immunotherapy of MSI Cancer: Facts and Hopes.
    Clin Cancer Res. 2024;30:1438-1447.
    PubMed     Abstract available
    
    
    
55. HANSFORD JR, Das A, McGee RB, Nakano Y, et al
    Update on cancer predisposition syndromes and surveillance guidelines for childhood brain tumors.
    Clin Cancer Res. 2024 Apr 4. doi: 10.1158/1078-0432.CCR-23-4033.
    PubMed     Abstract available
    
    
    
56. LYNCE F, Lin NU
    From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
    Clin Cancer Res. 2024;30:1217-1219.
    PubMed     Abstract available
    
    
    
57. STANISZEWSKA AD, Pilger D, Gill SJ, Jamal K, et al
    Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1.
    Clin Cancer Res. 2024;30:1338-1351.
    PubMed     Abstract available
    
    
    March 2024
58. CICCONE R, Quintarelli C, Camera A, Pezzella M, et al
    GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma.
    Clin Cancer Res. 2024 Mar 29. doi: 10.1158/1078-0432.CCR-23-1880.
    PubMed     Abstract available
    
    
    
59. DESAI PB, Karve A, Zawit M, Arora P, et al
    A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination with Standard Therapy in Recurrent High-Grade Gliomas.
    Clin Cancer Res. 2024 Mar 26. doi: 10.1158/1078-0432.CCR-23-3341.
    PubMed     Abstract available
    
    
    
60. SCHRECK KC, Strowd RE, Nabors LB, Ellingson BM, et al
    Response rate and molecular correlates to encorafenib and binimetinib in BRAF-V600E mutant high-grade glioma.
    Clin Cancer Res. 2024 Mar 6. doi: 10.1158/1078-0432.CCR-23-3241.
    PubMed     Abstract available
    
    
    February 2024
61. FANGUSARO J, Avery RA, Fisher MJ, Packer RJ, et al
    Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma Clinical Trials: An FDA Educational Symposium.
    Clin Cancer Res. 2024 Feb 15. doi: 10.1158/1078-0432.CCR-23-3386.
    PubMed     Abstract available
    
    
    
62. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
    Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Response.
    Clin Cancer Res. 2024;30:639.
    PubMed    
    
    
    
63. MANDONNET E
    Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma-Letter.
    Clin Cancer Res. 2024;30:638.
    PubMed    
    
    
    January 2024
64. ISER F, Hinz F, Hoffmann DC, Grassl N, et al
    Cerebrospinal fluid cfDNA sequencing for classification of central nervous system glioma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2907.
    PubMed     Abstract available
    
    
    
65. HABASHY KJ, Dmello C, Chen L, Arrieta VA, et al
    Paclitaxel and Carboplatin in Combination with Low-Intensity Pulsed Ultrasound for Glioblastoma.
    Clin Cancer Res. 2024 Jan 31. doi: 10.1158/1078-0432.CCR-23-2367.
    PubMed     Abstract available
    
    
    
66. LIM-FAT MJ, Iorgulescu JB, Rahman R, Bhave V, et al
    Clinical and genomic predictors of adverse events in newly diagnosed glioblastoma.
    Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3018.
    PubMed     Abstract available
    
    
    
67. MARGOLIN KA
    The Dance Between Tumor Molecular Biology and Antitumor Immune Response.
    Clin Cancer Res. 2024;30:257-259.
    PubMed     Abstract available
    
    
    
68. PETRONEK MS, Monga V, Bodeker KL, Kwofie M, et al
    Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM.
    Clin Cancer Res. 2024;30:283-293.
    PubMed     Abstract available
    
    
    
69. HAYASHI T, Tateishi K, Matsuyama S, Iwashita H, et al
    Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors.
    Clin Cancer Res. 2024;30:116-126.
    PubMed     Abstract available
    
    
    
70. CUI X, Wang Q, Liu X, Kang C, et al
    Levetiracetam: a potent sword against microglia polarization in gliomas.
    Clin Cancer Res. 2024 Jan 3. doi: 10.1158/1078-0432.CCR-23-3322.
    PubMed     Abstract available
    
    
    December 2023
71. GALBO PM, Madsen AT, Liu Y, Peng M, et al
    Functional Contribution and Clinical Implication of Cancer-Associated Fibroblasts in Glioblastoma.
    Clin Cancer Res. 2023 Dec 7. doi: 10.1158/1078-0432.CCR-23-0493.
    PubMed     Abstract available
    
    
    
72. SLOAN AR, Thapliyal M, Lathia JD
    New T-cell therapies for brain metastasis, CD133 in the driver's seat.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-3051.
    PubMed     Abstract available
    
    
    
73. KURZ SC, Zan E, Cordova C, Troxel AB, et al
    Evaluation of the SSTR2-targeted radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as imaging biomarker in patients with intracranial meningioma.
    Clin Cancer Res. 2023 Dec 1. doi: 10.1158/1078-0432.CCR-23-2533.
    PubMed     Abstract available
    
    
    
74. KAMSON DO, Puri S, Sang Y, Shi MJ, et al
    Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
    Clin Cancer Res. 2023;29:4863-4869.
    PubMed     Abstract available
    
    
    
75. DAS A, Tabori U, Sambira Nahum LC, Collins NB, et al
    Efficacy of Nivolumab in Pediatric Cancers with High Mutation Burden and Mismatch Repair Deficiency.
    Clin Cancer Res. 2023;29:4770-4783.
    PubMed     Abstract available
    
    
    November 2023
76. NABAVIZADEH A, Bagley SJ
    Exploiting iron metabolism as a therapeutic vulnerability in glioblastoma.
    Clin Cancer Res. 2023 Nov 20. doi: 10.1158/1078-0432.CCR-23-3027.
    PubMed     Abstract available
    
    
    
77. ARRIETA VA, Duerinck J, Burdett KB, Habashy KJ, et al
    ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-Guided Analysis.
    Clin Cancer Res. 2023 Nov 8. doi: 10.1158/1078-0432.CCR-23-1889.
    PubMed     Abstract available
    
    
    
78. BHATIA A, Moreno R, Reiner AS, Nandakumar S, et al
    Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma.
    Clin Cancer Res. 2023 Nov 1. doi: 10.1158/1078-0432.CCR-23-1180.
    PubMed     Abstract available
    
    
    October 2023
79. LI J, Hu H, Qin G, Bai F, et al
    Biomarkers of Pathological Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair Deficiency Colorectal Cancer.
    Clin Cancer Res. 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-2213.
    PubMed     Abstract available
    
    
    
80. GUO X, Qiu W, Li B, Qi Y, et al
    Hypoxia-induced neuronal activity in glioma patients polarizes microglia by potentiating RNA m6A demethylation.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0430.
    PubMed     Abstract available
    
    
    
81. GOTTARDO NG, Gajjar A
    Verschlimmbesserung: Craniospinal Radiotherapy is Essential in WNT Medulloblastoma Patients.
    Clin Cancer Res. 2023 Oct 12. doi: 10.1158/1078-0432.CCR-23-2331.
    PubMed     Abstract available
    
    
    
82. KIELISZEK AM, Mobilio D, Upreti D, Bloemberg D, et al
    Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases.
    Clin Cancer Res. 2023 Oct 3. doi: 10.1158/1078-0432.CCR-23-1735.
    PubMed     Abstract available
    
    
    September 2023
83. LUKAS RV, Horbinski C
    Glioma Response to IDH Inhibition: Real-World Experience.
    Clin Cancer Res. 2023 Sep 22. doi: 10.1158/1078-0432.CCR-23-2164.
    PubMed     Abstract available
    
    
    
84. JOHNSON M, Bell A, Lauing KL, Ladomersky E, et al
    Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence.
    Clin Cancer Res. 2023 Sep 19. doi: 10.1158/1078-0432.CCR-23-0834.
    PubMed     Abstract available
    
    
    
85. FERMI V, Warta R, Wollner A, Lotsch C, et al
    Effective reprogramming of patient-derived M2-polarized glioblastoma-associated microglia/macrophages by treatment with GW2580.
    Clin Cancer Res. 2023 Sep 8. doi: 10.1158/1078-0432.CCR-23-0576.
    PubMed     Abstract available
    
    
    August 2023
86. KINSLOW CJ, Rae AI, Taparra K, Kumar P, et al
    MGMT promoter methylation predicts overall survival after chemotherapy for 1p/19q-codeleted gliomas.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1295. doi: 10.1158/1078-0432.CCR-23-1295.
    PubMed     Abstract available
    
    
    
87. NAYYAR N, de Sauvage MA, Chuprin J, Sullivan EM, et al
    CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.
    Clin Cancer Res. 2023 Aug 23:CCR-23-0433. doi: 10.1158/1078-0432.CCR-23-0433.
    PubMed     Abstract available
    
    
    
88. BARBATO MI, Nashed J, Bradford D, Ren Y, et al
    FDA Approval Summary: Dabrafenib in combination with trametinib for BRAF V600E mutation-positive low-grade glioma.
    Clin Cancer Res. 2023 Aug 23:CCR-23-1503. doi: 10.1158/1078-0432.CCR-23-1503.
    PubMed     Abstract available
    
    
    
89. TEW BY, Kalfa AJ, Yang Z, Hurth KM, et al
    ATM-inhibitor AZD1390 is a radiosensitizer for breast cancer CNS metastasis.
    Clin Cancer Res. 2023 Aug 16:CCR-23-0290. doi: 10.1158/1078-0432.CCR-23-0290.
    PubMed     Abstract available
    
    
    
90. SRINIVASAN ES, Liu Y, Odion RA, Chongsathidkiet P, et al
    Gold Nanostars Obviate Limitations to Laser Interstitial Thermal Therapy (LITT) for the Treatment of Intracranial Tumors.
    Clin Cancer Res. 2023;29:3214-3224.
    PubMed     Abstract available
    
    
    
91. ELLINGSON BM, Hagiwara A, Morris CJ, Cho NS, et al
    Depth of radiographic response (DpR) and time to tumor regrowth (TTG) predicts overall survival following anti-VEGF therapy in recurrent glioblastoma.
    Clin Cancer Res. 2023 Aug 4:CCR-23-1235. doi: 10.1158/1078-0432.CCR-23-1235.
    PubMed     Abstract available
    
    
    July 2023
92. COHEN KJ, Munjapara V, Aguilera D, Castellino RC, et al
    A pilot study omitting radiation in the treatment of children with newly diagnosed Wnt-activated medulloblastoma.
    Clin Cancer Res. 2023 Jul 27:CCR-23-0348. doi: 10.1158/1078-0432.CCR-23-0348.
    PubMed     Abstract available
    
    
    
93. LAL B, Kulkarni A, McDermott J, Rais R, et al
    Preclinical efficacy of LP-184, a tumor site activated synthetic lethal therapeutic, in glioblastoma.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0673. doi: 10.1158/1078-0432.CCR-23-0673.
    PubMed     Abstract available
    
    
    
94. KESSLER T, Schrimpf D, Doerner L, Hai L, et al
    Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial.
    Clin Cancer Res. 2023 Jul 26:CCR-23-0926. doi: 10.1158/1078-0432.CCR-23-0926.
    PubMed     Abstract available
    
    
    
95. XU Q, Huang K, Meng X, Weng Y, et al
    Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma.
    Clin Cancer Res. 2023 Jul 21:CCR-23-0388. doi: 10.1158/1078-0432.CCR-23-0388.
    PubMed     Abstract available
    
    
    
96. YUAN W, Zhang Q, Gu D, Lu C, et al
    Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages.
    Clin Cancer Res. 2023 Jul 13:CCR-22-3273. doi: 10.1158/1078-0432.CCR-22-3273.
    PubMed     Abstract available
    
    
    June 2023
97. LY KI, Richardson LG, Liu M, Muzikansky A, et al
    Bavituximab decreases immunosuppressive myeloid-derived suppressor cells in newly diagnosed glioblastoma patients.
    Clin Cancer Res. 2023 Jun 16:CCR-23-0203. doi: 10.1158/1078-0432.CCR-23-0203.
    PubMed     Abstract available
    
    
    
98. FOOTE MB, Argiles G, Rousseau B, Segal NH, et al
    Facts and hopes in colorectal cancer immunotherapy.
    Clin Cancer Res. 2023 Jun 16:CCR-22-2176. doi: 10.1158/1078-0432.CCR-22-2176.
    PubMed     Abstract available
    
    
    
99. CHITTIBOINA P, Mandal D, Bugarini A, Asuzu DT, et al
    Proteostasis Modulation in Germline Missense von Hippel Lindau Disease.
    Clin Cancer Res. 2023;29:2199-2209.
    PubMed     Abstract available
    
    
    
100. KABRAJI S, Lin NU
     Keeping it in the family: HER3 as a target in brain metastases.
     Clin Cancer Res. 2023 Jun 12:CCR-23-1107. doi: 10.1158/1078-0432.CCR-23-1107.
     PubMed     Abstract available
     
     
     
101. MACK SC, Bertrand KC
     A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
     Clin Cancer Res. 2023 Jun 1:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-0472.
     PubMed     Abstract available
     
     
     May 2023
102. SHI L, Chen H, Chen K, Zhong C, et al
     The DRD2 antagonist haloperidol mediates autophagy-induced ferroptosis to increase temozolomide sensitivity by promoting endoplasmic reticulum stress in glioblastoma.
     Clin Cancer Res. 2023 May 30:CCR-22-3971. doi: 10.1158/1078-0432.CCR-22-3971.
     PubMed     Abstract available
     
     
     
103. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
     Taming Glioblastoma in "Real Time": Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology.
     Clin Cancer Res. 2023 May 25:OF1-OF5. doi: 10.1158/1078-0432.CCR-23-0009.
     PubMed     Abstract available
     
     
     
104. MACK SC, Bertrand KC
     A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
     Clin Cancer Res. 2023 May 15:CCR-23-0472. doi: 10.1158/1078-0432.CCR-23-0472.
     PubMed     Abstract available
     
     
     
105. DE GODOY LL, Chawla S, Brem S, Mohan S, et al
     Taming Glioblastoma in 'Real Time': Integrating Multimodal Advanced Neuroimaging/AI Tools Towards Creating a Robust and Therapy Agnostic Model for Response Assessment in Neuro-Oncology".
     Clin Cancer Res. 2023 May 9:CCR-23-0009. doi: 10.1158/1078-0432.CCR-23-0009.
     PubMed     Abstract available
     
     
     April 2023
106. THIESLER H, Gretenkort L, Hoffmeister L, Albers I, et al
     Proinflammatory macrophage activation by the polysialic acid-Siglec-16 axis is linked to increased survival of glioblastoma patients.
     Clin Cancer Res. 2023 Apr 14:CCR-22-1488. doi: 10.1158/1078-0432.CCR-22-1488.
     PubMed     Abstract available
     
     
     
107. TOMASICH E, Steindl A, Paiato C, Hatziioannou T, et al
     Frequent overexpression of HER3 in brain metastases from breast and lung cancer.
     Clin Cancer Res. 2023 Apr 10:CCR-23-0020. doi: 10.1158/1078-0432.CCR-23-0020.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.